NDA 210795 · Glaxosmithkline
Krintafel
Tafenoquine Succinate · Oral
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Nov 16, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Jul 20, 2018
Approved uses
1
Original approval plus efficacy supplements
Registered trials
39
7 Phase 3, 8 recruiting
FAERS reports
11
7 serious, 3 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 2, 2023.
KRINTAFEL is indicated for the radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged 16 years and older who are receiving chloroquine therapy for acute P. vivax infection [see Dosage and Administration ( 2.2 )] . Limitations of Use • KRINTAFEL is NOT indicated for the treatment of acute P. vivax malaria. • Concomitant use of KRINTAFEL with antimalarials other than chloroquine is not recommended because of the risk of recurrence of P. vivax malaria [see Warnings and Precautions ( 5.6 )] . KRINTAFEL is an antimalarial indicated for the radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged 16 years and older who are receiving chloroquine therapy for acute P. vivax infection. ( 1 ) Limitations of Use • KRINTAFEL is NOT indicated for the treatment of acute P. vivax malaria. ( 1 ) • The concomitant use of KRINTAFEL with antimalarials other than chloroquine is not recommended because of the risk of recurrence of P. vivax malaria. ( 1 , 5.6 )
Mechanism: Tafenoquine is an 8-aminoquinoline antimalarial drug [see Microbiology ( 12.4 )].
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 20, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
1 products under this application
- KRINTAFEL · TAFENOQUINE SUCCINATE EQ 150MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Tafenoquine" as an intervention, any sponsor and status, largest first.
- FocaL Mass Drug Administration for Vivax Malaria EliminationPivotal-lookingRecruiting
University of California, San FranciscoAcademic, hospital or other
NCT05690841 · 7,530 participants (planned) · Start Oct 14, 2024 · Primary completion May 1, 2027
Drug: Focal Mass Drug Administration (fMDA) · For: Plasmodium Vivax Malaria; Malaria
Sites: Iquitos, Peru
- Radical CUREfor MAlaria Among Highly Mobile and Hard-to-reach Populations in the Guyanese ShieldCompleted
Centre Hospitalier de CayenneAcademic, hospital or other
NCT05540470 · 1,991 participants · Start Sep 12, 2022 · Primary completion Mar 31, 2025
Drug: PART; Malakit · For: Malaria, Vivax
Sites: Oiapoque, Brazil; Paramaribo, Suriname
Shoklo Malaria Research UnitAcademic, hospital or other
NCT06575647 · 1,242 participants · Start Feb 19, 2025 · Primary completion Oct 4, 2025
Drug: Tafenoquine · For: Malaria; Malaria, Vivax; Plasmodium Vivax and 1 more
Sites: Mae Sot, Thailand
- A Revised Tafenoquine Dose to Improve Radical Cure for Vivax MalariaPivotal-lookingRecruiting
Menzies School of Health ResearchAcademic, hospital or other
NCT06148792 · 1,090 participants (planned) · Start May 10, 2024 · Primary completion Mar 1, 2027
Drug: Tafenoquine; Primaquine · For: Vivax Malaria
Sites: Manaus, Brazil; Arba Minch, Ethiopia; Hanura, Indonesia · 4 sites in all
- Effectiveness of Novel Approaches to Radical Cure With Tafenoquine and PrimaquinePivotal-lookingCompleted
Menzies School of Health ResearchAcademic, hospital or other
NCT04411836 · 960 participants · Start Apr 25, 2021 · Primary completion Sep 30, 2024
Drug: Tafenoquine; Primaquine · For: Vivax Malaria; Plasmodium Vivax; Malaria, Vivax and 1 more
Sites: Pursat, Cambodia; Kampong Speu, Cambodia; Stung Treng, Cambodia · 6 sites in all
- Ph 2B/3 Tafenoquine (TFQ) Study in Prevention of Vivax RelapsePivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01376167 · 851 participants · Start Apr 24, 2014 · Primary completion Nov 18, 2016
Drug: Chloroquine 600mg; Chloroquine 300mg and 9 more · For: Malaria, Vivax
Sites: Bāndarban, Bangladesh; Manaus, Brazil; Porto Velho, Brazil · 14 sites in all
- Southeast Asia Dose Optimization of TafenoquinePivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT04704999 · 820 participants (planned) · Start Jul 22, 2024 · Primary completion Oct 4, 2027
Drug: Tafenoquine; Chloroquine and 3 more · For: Plasmodium Vivax Malaria
Sites: Siem Reap, Cambodia; Jayapura, Indonesia; Vientiane, Laos · 6 sites in all
- ACT vs CQ With Tafenoquine for P. Vivax Mono-infectionPivotal-lookingRecruiting
Shoklo Malaria Research UnitAcademic, hospital or other
NCT05788094 · 606 participants (planned) · Start Jun 26, 2023 · Primary completion Feb 28, 2026
Drug: Dihydroartemisinin-piperaquine plus tafenoquine (450 mg adult dose); Chloroquine plus Tafenoquine (450 mg adult dose) and 1 more · For: Malaria; Malaria, Vivax; Plasmodium Vivax Malaria
Sites: Mae Sot, Thailand
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective3
- off label use3
- bacteraemia2
- blood fibrinogen decreased2
- blood lactate dehydrogenase increased2
- blood triglycerides increased2
- candida infection2
- drug effective for unapproved indication2
- haemolysis2
- haemolytic anaemia2
- haemophagocytic lymphohistiocytosis2
- infection2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2019 | 2 |
| 2020 | 1 |
| 2022 | 4 |
| 2023 | 2 |
| 2024 | 1 |
| 2026 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Tafenoquine: a toxicity overview.
Chu CS, Hwang J · Expert Opin Drug Saf 2021 · Meta-Analysis, Systematic Review
- Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Llanos-Cuentas A, Lacerda MVG, Hien TT, et al. · N Engl J Med 2019 · Clinical Trial, Phase III, Comparative Study
- Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.
Rodrigo C, Rajapakse S, Fernando D · Cochrane Database Syst Rev 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.
Rajapakse S, Rodrigo C, Fernando SD · Cochrane Database Syst Rev 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Efficacy and safety of tafenoquine for malaria chemoprophylaxis (1998-2020): A systematic review and meta-analysis.
Maier JD, Siegfried S, Gültekin N, et al. · Travel Med Infect Dis 2021 · Meta-Analysis, Systematic Review
- Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
Lacerda MVG, Llanos-Cuentas A, Krudsood S, et al. · N Engl J Med 2019 · Clinical Trial, Phase II, Clinical Trial, Phase III
Sponsor: GSK
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.